Login / Signup

Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes.

Lorinc Sandor PongorChristopher W SchultzLorenzo RinaldiDarawalee WangsaChristophe E RedonNobuyuki TakahashiGavriel FialkoffParth DesaiYang ZhangSandra Sczerba BurkettNadav HermoniNoa VilkJenia GutinGergely RonaYongmei ZhaoSamantha NicholsRasa VilimasLinda SciutoChante GrahamJuan Manuel CaravacaSevilay TuranTsai-Wei ShenVinodh N RajapakseRajesh KumarDeep UpadhyaySuresh KumarYoo-Sun KimNitin RoperBao TranStephen M HewittDavid E KleinerMirit I AladjemNir FriedmanGordon L HagerYves PommierThomas RiedAnish Thomas
Published in: Cancer discovery (2023)
Small-cell lung cancer is an aggressive neuroendocrine lung cancer. Oncogenic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC amplification and phenotypic plasticity, characterized by neuroendocrine and non-neuroendocrine cell states is not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization to find extrachromosomal DNA (ecDNA) as a primary source of MYC amplifications and driver fusions in SCLC. ecDNAs bring to proximity enhancer elements and oncogenes, creating SCLC transcription-amplifying units, driving exceptionally high MYC gene dosage. We demonstrate that cell-free nucleosome profiling can non-invasively detect ecDNA amplifications in plasma, facilitating its genome-wide interrogation in SCLC and other cancers. Altogether, our work provides the first comprehensive map of SCLC ecDNA and describe a new mechanism that governs MYC-driven SCLC heterogeneity. ecDNA-enabled transcriptional flexibility may explain the significantly worse survival outcomes of SCLC tumors harboring complex ecDNA amplifications.
Keyphrases